Corrigendum to "Navigating the complexity of PI3K/AKT pathway in HER-2 negative breast cancer: Biomarkers and beyond" [Crit. Rev. Oncol./Hematol. 200C (2024) 104404]

Affiliations

¹ Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy. Electronic address: marianna.sirico@irst.emr.it.
² Humanitas Clinical and Research Center - IRCCS, Humanitas Cancer Center, via Manzoni 56, Rozzano, Milan 20089, Italy; Academic Trials Promoting Team, Institut Jules Bordet and l'Université Libre de Bruxelles (U.L.B), 90, Rue Meylemeersch, Anderlecht, Brussels 1070, Belgium.
³ Academic Trials Promoting Team, Institut Jules Bordet and l'Université Libre de Bruxelles (U.L.B), 90, Rue Meylemeersch, Anderlecht, Brussels 1070, Belgium; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy; Department of Medical Oncology, U.O. Clinical di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
⁴ Academic Trials Promoting Team, Institut Jules Bordet and l'Université Libre de Bruxelles (U.L.B), 90, Rue Meylemeersch, Anderlecht, Brussels 1070, Belgium.
⁵ Faculty of Medicine, Department of Surgery and Cancer, Imperial College London, United Kingdom.
⁶ Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.

Published Erratum

M Sirico et al. Crit Rev Oncol Hematol. 2024 Dec.

. 2024 Dec:204:104542.

doi: 10.1016/j.critrevonc.2024.104542. Epub 2024 Nov 4.

¹ Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy. Electronic address: marianna.sirico@irst.emr.it.
² Humanitas Clinical and Research Center - IRCCS, Humanitas Cancer Center, via Manzoni 56, Rozzano, Milan 20089, Italy; Academic Trials Promoting Team, Institut Jules Bordet and l'Université Libre de Bruxelles (U.L.B), 90, Rue Meylemeersch, Anderlecht, Brussels 1070, Belgium.
³ Academic Trials Promoting Team, Institut Jules Bordet and l'Université Libre de Bruxelles (U.L.B), 90, Rue Meylemeersch, Anderlecht, Brussels 1070, Belgium; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy; Department of Medical Oncology, U.O. Clinical di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
⁴ Academic Trials Promoting Team, Institut Jules Bordet and l'Université Libre de Bruxelles (U.L.B), 90, Rue Meylemeersch, Anderlecht, Brussels 1070, Belgium.
⁵ Faculty of Medicine, Department of Surgery and Cancer, Imperial College London, United Kingdom.
⁶ Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.

No abstract available

Erratum for

Navigating the complexity of PI3K/AKT pathway in HER-2 negative breast cancer: biomarkers and beyond.
Sirico M, Jacobs F, Molinelli C, Nader-Marta G, Debien V, Dewhurst HF, Palleschi M, Merloni F, Gianni C, De Giorgi U, de Azambuja E. Sirico M, et al. Crit Rev Oncol Hematol. 2024 Aug;200:104404. doi: 10.1016/j.critrevonc.2024.104404. Epub 2024 May 28. Crit Rev Oncol Hematol. 2024. PMID: 38815877 Review.